“If you are admitted to hospital, don’t take hydroxychloroquine, it doesn’t work,” Martin Landray, deputy chief investigator of the U.K.-based Recovery Trial told The Guardian.
The trial has been called a ‘gold standard’ for looking at potential Coronavirus treatments.
They have halted their hydroxychloroquine arm after finding that there was “no clinical benefit” from using the drug in hospitalised patients with Coronavirus.
Many countries have permitted the use of the controversial drug for COVID-19 patients following international claims that it was a cure. Even U.S. President Donald Trump has backed the drug saying he was taking a dose every day to protect himself.
According to the Trial no significant difference was seen in their sample of 1,542 patients who were randomly receiving hydroxychloroquine, when compared to the 3,132 patients who were not. Over 28 days, 25.7% of patients on hydroxychloroquine died compared with 23.5% of the others. The difference was not statistically significant enough to show it works.
Other arms in the Trial, which had enrolled more than 11,000 patients across the country, will continue looking at dosage of Lopinavir-Ritonavir (a commonly used HIV treatment), low-dose Dexamethasone (a type pf steroid), Azithromycin (a common antibiotic), Tocilizumab (an injectable anti-inflammatory) and Convalescent plasma collected from recovered donors who now possess the antibodies against the virus.